Is Intra-Cellular Therapies, Inc. (ITCI) a Sell? The Stock Declines Again

Investors sentiment increased to 1.4 in Q2 2019. Its up 0.07, from 1.33 in 2019Q1. It increased, as 15 investors sold Intra-Cellular Therapies, Inc. shares while 25 reduced holdings. 13 funds opened positions while 43 raised stakes. 34.58 million shares or 6.28% less from 36.90 million shares in 2019Q1 were reported.
Moreover, Bnp Paribas Arbitrage has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Tower Research Capital Ltd Limited Liability Company (Trc) stated it has 1,885 shares or 0% of all its holdings. Jacobs Levy Equity Management Inc holds 116,684 shares or 0.02% of its portfolio. State Of Wisconsin Board accumulated 64,900 shares. Gemmer Asset Limited Liability holds 0.03% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 10,000 shares. Art Ltd Liability Company owns 33,221 shares. Barclays Public Ltd Co invested in 0% or 39,914 shares. Price T Rowe Associate Inc Md stated it has 355,500 shares. Cubist Systematic Strategies Ltd invested in 0% or 19,620 shares. Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 2,671 shares. California Pub Employees Retirement invested in 0% or 59,100 shares. Wasatch Advsrs Incorporated reported 2.35 million shares. Weiss Multi holds 30,000 shares or 0.01% of its portfolio. Geode Cap Mgmt Ltd stated it has 644,414 shares. 20,835 were accumulated by Proshare Advsr Limited Liability.

Since May 14, 2019, it had 4 buys, and 0 sales for $9.29 million activity.

The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a huge mover today! The stock decreased 4.97% or $0.52 during the last trading session, reaching $9.94. About 1.08M shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 57.38% since September 13, 2018 and is downtrending. It has underperformed by 57.38% the S&P500.
The move comes after 7 months negative chart setup for the $548.42 million company. It was reported on Sep, 13 by We have $9.05 PT which if reached, will make NASDAQ:ITCI worth $49.36M less.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on November, 6. They expect $-0.89 EPS, down 17.11 % or $0.13 from last year’s $-0.76 per share. After $-0.68 actual EPS reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts 30.88 % negative EPS growth.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 2 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intra-Cellular Therapies has $2100 highest and $1600 lowest target. $18.50’s average target is 86.12% above currents $9.94 stock price. Intra-Cellular Therapies had 3 analyst reports since May 16, 2019 according to SRatingsIntel. JMP Securities maintained the stock with “Market Outperform” rating in Thursday, August 8 report.

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: which released: “Health Care Sector Update for 07/08/2019: SGMO, PFE, ITCI, PRVL, JNJ, ABT, MRK, AMGN – Nasdaq” on July 08, 2019, also with their article: “Oasmia Pharmaceutical and Xenetic Biosciences among healthcare gainers; Intra-Cellular Therapies leads the losers – Seeking Alpha” published on July 08, 2019, published: “30 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” on June 13, 2019. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: and their article: “The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings – Yahoo Finance” published on July 06, 2019 as well as‘s news article titled: “Intra-Cellular Therapies: Caution Ahead Of Major Events This Quarter – Seeking Alpha” with publication date: July 02, 2019.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company has market cap of $548.42 million. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.